Fractyl Health Reports Q3 2026 Results with Improved Net Loss and Positive REMAIN-1 Clinical Data

Fractyl Health (GUTS) reported a net loss of $14.2 million for the third quarter of 2026, a significant improvement from the previous year driven by reduced operating expenses and favorable changes in warrant liability fair value. The company is undergoing a strategic pivot to focus exclusively on its Revita program, which included a 45% workforce reduction and a target to reduce quarterly operating cash spending by 50% by mid-2027. Clinical results from the REMAIN-1 pivotal study showed strong efficacy for the Revita program, with participants maintaining 80% of tirzepatide-induced weight loss at six months. The data demonstrated a dose-dependent effect and met primary endpoints with statistical significance (p=0.0023). Management is positioning the company to capture the market of patients discontinuing GLP-1 therapies, targeting an initial launch across 30 to 50 specialized bariatric centers.

4 articles from 2 sources · updated

Coverage